Renaissance Technologies's IONS Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 486,714 shares of Ionis Pharmaceuticals, Inc. (IONS) worth $31.84 M, representing 0.04% of the portfolio. First purchased in 2015-Q4, this long-term strategic position has been held for 40 quarters.
Based on 13F filings, Renaissance Technologies has maintained a strategic position in IONS, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2019, adding 1.65 M shares. Largest reduction occurred in Q4 2020, reducing 721,819 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Ionis Pharmaceuticals (IONS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Ionis Pharmaceuticals (IONS) Trades by Renaissance Technologies
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2015 | +135,314 | New Buy | 135,314 | $61.93 |
| Q1 2016 | -75,914 | Reduce 56.10% | 59,400 | $40.51 |
| Q2 2016 | +123,700 | Add 208.25% | 183,100 | $23.29 |
| Q3 2016 | +91,714 | Add 50.09% | 274,814 | $36.64 |
| Q4 2016 | +174,700 | Add 63.57% | 449,514 | $47.83 |
| Q1 2017 | -136,300 | Reduce 30.32% | 313,214 | $40.20 |
| Q2 2017 | -230,800 | Reduce 73.69% | 82,414 | $50.87 |
| Q3 2017 | -82,414 | Sold Out | 82,414 | $0.00 |
| Q1 2018 | +227,714 | New Buy | 227,714 | $44.08 |
| Q2 2018 | -117,800 | Reduce 51.73% | 109,914 | $41.67 |
| Q3 2018 | -109,914 | Sold Out | 109,914 | $0.00 |
| Q2 2019 | +1.76 M | New Buy | 1.76 M | $64.27 |
| Q3 2019 | +57,700 | Add 3.29% | 1.81 M | $59.91 |
| Q4 2019 | +225,700 | Add 12.45% | 2.04 M | $60.41 |
| Q1 2020 | -350,300 | Reduce 17.18% | 1.69 M | $47.28 |
| Q2 2020 | +64,456 | Add 3.82% | 1.75 M | $58.96 |
| Q3 2020 | -285,700 | Reduce 16.30% | 1.47 M | $47.45 |
| Q4 2020 | -721,819 | Reduce 49.20% | 745,348 | $56.54 |
| Q1 2021 | -157,934 | Reduce 21.19% | 587,414 | $44.96 |
| Q2 2021 | +189,000 | Add 32.17% | 776,414 | $39.89 |
| Q3 2021 | -678,700 | Reduce 87.41% | 97,714 | $33.54 |
| Q4 2021 | +133,100 | Add 136.21% | 230,814 | $30.43 |
| Q1 2022 | -95,900 | Reduce 41.55% | 134,914 | $37.04 |
| Q2 2022 | +479,900 | Add 355.71% | 614,814 | $37.02 |
| Q3 2022 | +252,900 | Add 41.13% | 867,714 | $44.23 |
| Q4 2022 | +311,100 | Add 35.85% | 1.18 M | $0.04 |
| Q1 2023 | -542,500 | Reduce 46.02% | 636,314 | $0.04 |
| Q2 2023 | -265,814 | Reduce 41.77% | 370,500 | $0.04 |
| Q3 2023 | -100,700 | Reduce 27.18% | 269,800 | $45.36 |
| Q4 2023 | -157,386 | Reduce 58.33% | 112,414 | $50.59 |
| Q1 2024 | +67,300 | Add 59.87% | 179,714 | $43.35 |
| Q2 2024 | +69,800 | Add 38.84% | 249,514 | $47.66 |
| Q3 2024 | -59,000 | Reduce 23.65% | 190,514 | $40.06 |
| Q4 2024 | +15,000 | Add 7.87% | 205,514 | $34.96 |
| Q1 2025 | -52,000 | Reduce 25.30% | 153,514 | $30.17 |
| Q2 2025 | +117,200 | Add 76.34% | 270,714 | $39.51 |
| Q3 2025 | +216,000 | Add 79.79% | 486,714 | $65.42 |
Renaissance Technologies's Ionis Pharmaceuticals Investment FAQs
Renaissance Technologies first purchased Ionis Pharmaceuticals, Inc. (IONS) in Q4 2015, acquiring 135,314 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Ionis Pharmaceuticals, Inc. (IONS) for 40 quarters since Q4 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's largest addition to Ionis Pharmaceuticals, Inc. (IONS) was in Q2 2019, adding 1,755,311 shares worth $112.81 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 486,714 shares of Ionis Pharmaceuticals, Inc. (IONS), valued at approximately $31.84 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Ionis Pharmaceuticals, Inc. (IONS) represents approximately 0.04% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies's peak holding in Ionis Pharmaceuticals, Inc. (IONS) was 2,038,711 shares, as reported at the end of Q4 2019. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.